Doubling Down
PRF funds a combination drug trial with lonafarnib + everolimus. Although the trial finds no significant improvement over lonafarnib alone, the results inform future research directions.
PRF funds a combination drug trial with lonafarnib + everolimus. Although the trial finds no significant improvement over lonafarnib alone, the results inform future research directions.
